KMO and nervous system disorder: During past two decades, a series of studies showed Ro 61-8048, kynurenine 3-monooxygenase inhibitor, a potential therapeutic target for neurodegenerative and neurologic disorders and promoted increased levels of the KA in the brain that reduced the cannabinoid abuse and prevented relapse (Röver et al., 1997; Justinova et al., 2013; Secci et al., 2017; Gao et al., 2018).